文献速递妇科

经腹超声引导下经皮微波消融治疗症状性子宫腺肌病的疗效:一项回顾性队列研究

Efficacy of Transabdominal Ultrasound-guided Percutaneous Microwave Ablation in the Treatment of Symptomatic Adenomyosis: A Retrospective Cohort Study.
PubMed 文献 · J Minim Invasive Gynecol · 2022-11-14

回顾性队列研究纳入2019年5月至2021年10月拒绝子宫切除的症状性子宫腺肌病患者107例,按病灶累及范围分为局灶组47例与非局灶组60例,均接受经腹超声引导下经皮微波消融(PMWA)。治疗后子宫体积、CA125水平下降,血红蛋白升高,症状与生活质量评分、痛经视觉模拟评分及月经量评分均改善(均P<.05),两组治疗后各项指标及临床应答率相似(P>.05)。结论认为PMWA对局灶性与非局灶性症状性子宫腺肌病均有良好且相似的短期疗效。

要点

  • PMWA治疗后子宫体积与CA125水平显著下降、血红蛋白显著升高(均P<.05)。
  • 治疗后症状严重程度量表、生活质量量表、痛经视觉模拟评分及月经量评分均显著改善(均P<.05)。
  • 非局灶组治疗前贫血更重、症状评分更高,但治疗后两组各项指标及临床应答率相似(P>.05)。

核心结论

  • PMWA对症状性局灶性与非局灶性子宫腺肌病均有良好且相似的短期疗效。

研究设计与样本

  • 回顾性队列研究,于福建医科大学附属龙岩第一医院开展。
  • 2019年5月至2021年10月纳入107例拒绝子宫切除的症状性子宫腺肌病患者接受PMWA。
  • 按病灶累及范围分为局灶组47例(局灶性子宫腺肌病40例、腺肌瘤7例)与非局灶组60例(弥漫性36例、混合性24例)。
  • 收集术前基线资料、术后3、6、12个月疗效指标及术中术后并发症。

主要发现

  • 治疗后子宫体积与CA125水平显著下降,血红蛋白水平显著升高(均P<.05)。
  • 子宫肌瘤症状与健康相关生活质量评分(含症状严重程度量表与健康相关生活质量量表)、痛经视觉模拟评分及月经量评分均显著改善(均P<.05)。
  • 1例患者复发。
  • 多数不良事件(72.0%)为轻度。
  • 非局灶组治疗前贫血严重程度更高、症状严重程度量表与月经量评分更高、健康相关生活质量量表更低、子宫肌层受累范围与程度更大、子宫体积更大,但治疗后两组子宫体积、子宫体积缩小率、CA125水平、血红蛋白水平、子宫肌瘤症状与健康相关生活质量评分、痛经视觉模拟评分、月经量评分及临床应答率相似(P>.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: To evaluate and compare the clinical efficacy of transabdominal ultrasound-guided percutaneous microwave ablation (PMWA) in the treatment of symptomatic focal and nonfocal adenomyosis. DESIGN: Retrospective cohort study. SETTING: Longyan First Affiliated Hospital of Fujian Medical University. PATIENTS: From May 2019 to October 2021, 107 patients with symptomatic adenomyosis who refused hysterectomy received PMWA. INTERVENTIONS: Patients were divided into a focal group (n = 47, including 40 focal adenomyosis and 7 adenomyoma cases) and a nonfocal group (n = 60, including 36 diffuse and 24 mixed adenomyosis cases) according to the extent of lesion involvement. MEASUREMENTS AND MAIN RESULTS: We collected and analyzed preoperative baseline data on patient characteristics; postoperative efficacy measures at 3, 6, and 12 months; and intraoperative and postoperative complications. There was a significant post-treatment reduction in the uterine corpus volume and cancer antigen 125 levels, an increase in hemoglobin levels, and an improvement in the Uterine Fibroid Symptom and Health-related Quality of Life scores (consisting of the Symptom Severity Scale and the Health-related Quality of Life scale), dysmenorrhea visual analog scale, and menstrual volume score (MVS) (all p <.05). One patient had recurrence. Most adverse events (72.0%) were mild. Although the nonfocal group had significantly greater anemia severity, higher Symptom Severity Scale and MVS, lower Health-related Quality of Life scale, greater extent and severity of myometrial involvement, and larger uterine corpus volume, after treatment, the uterine corpus volume, uterine corpus reduction rate, cancer antigen 125 levels, hemoglobin levels, Uterine Fibroid Symptom and Health-related Quality of Life score, dysmenorrhea visual analog scale, MVS score, and clinical response rate were similar between the groups (p >.05). CONCLUSION: PMWA had good, similar, short-term efficacy for symptomatic focal and nonfocal adenomyosis.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Li S, Li Z, Lin M, et al. Efficacy of Transabdominal Ultrasound-guided Percutaneous Microwave Ablation in the Treatment of Symptomatic Adenomyosis: A Retrospective Cohort Study. J Minim Invasive Gynecol. 2022. PMID: 36384213. doi:10.1016/j.jmig.2022.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。